Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2006

01-08-2006

The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth

Authors: Jana Divisova, Isere Kuiatse, ZaWaunyka Lazard, Heidi Weiss, Franzanne Vreeland, Darryl L. Hadsell, Rachel Schiff, C. Kent Osborne, Adrian V. Lee

Published in: Breast Cancer Research and Treatment | Issue 3/2006

Login to get access
Metadata
Title
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth
Authors
Jana Divisova
Isere Kuiatse
ZaWaunyka Lazard
Heidi Weiss
Franzanne Vreeland
Darryl L. Hadsell
Rachel Schiff
C. Kent Osborne
Adrian V. Lee
Publication date
01-08-2006
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9168-1

Other articles of this Issue 3/2006

Breast Cancer Research and Treatment 3/2006 Go to the issue

Clinical trial

Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial

Epidemiology

Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians

Clinical trial

Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients

Clinical trial

Predictors of local recurrence after conservative surgery and whole-breast irradiation

Erratum

High Prognostic Significance of Residual Disease After Neoadjuvant Chemotherapy: a Retrospective Study in 710 Patients with Operable Breast Cancer

Preclinical study

Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits